

An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader for the Treatment of Primary and Inhibitor-Resistant Solid Tumors

Ya-Wen Lu, Ph.D. Associate Director, Discovery Biology

7TH Annual TPD & Induced Proximity Summit 2024 Boston, MA October 29, 2024

Important Notice and Disclaimers

This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "outlook," "plan," "predict," "should," "will," and similar expressions and their variants, as they relate to Nurix Therapeutics, Inc. ("Nurix", the "Company," "we," "us" or "our"), may identify forwardlooking statements. All statements that reflect Nurix's expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding our future financial or business plans; our future performance, prospects and strategies; future conditions, trends, and other financial and business matters; our current and prospective drug candidates; the planned timing and conduct of the clinical trial programs for our drug candidates; the planned timing for the provision of clinical updates and initial findings from our clinical studies; the potential benefits of our collaborations, including potential milestone and sales-related payments; the potential advantages of our DELigase™ platform and drug candidates; the extent to which our scientific approach, our DELigase™ platform, targeted protein modulation, and Degrader-Antibody Conjugates may potentially address a broad range of diseases; the extent animal model data predicts human efficacy; and the timing and success of the development and commercialization of our current and anticipated drug candidates. Forward-looking statements reflect Nurix's current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix's actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) risks and uncertainties related to Nurix's ability to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) the timing and results of clinical trials; (iii) Nurix's ability to fund development activities and achieve development goals; (iv) risks and uncertainties relating to the timing and receipt of payments from Nurix's collaboration partners, including milestone payments and royalties on future potential product sales; (v) the impact of macroeconomic events and conditions, including increasing financial market volatility and uncertainty, inflation, interest rate fluctuations, instability in the global banking system, uncertainty with respect to the federal budget and debt ceiling, the impact of war, military or regional conflicts, and global health pandemics, on Nurix's clinical trials and operations; (vi) Nurix's ability to protect intellectual property and (vii) other risks and uncertainties described under the heading "Risk Factors" in Nurix's Quarterly Report on Form 10-Q for the fiscal guarter ended August 31, 2024, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this presentation speak only as of the date of this presentation, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.


Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal estimates and research are reliable, such estimates and research have not been verified by any independent source.



Drug Discovery Pipeline Strategy

Meeting The Needs of Patients With Breakthrough Therapies

Clinically validated targets where inhibitors fail to address resistance and scaffolding



Kinase targets in cancer

BTK – B-cell malignancies and I&I **BRAF** – solid tumors

Unmet medical need due to insufficient efficacy or tolerability

IRAK4 Inhibitor

IRAK4

Reduces IRAK4-Dependent Cytokine Production

IRAK4 Degrader




Eliminates IRAK4-Dependent Cytokine Production

Signaling proteins with scaffolding function

IRAK4 - rheumatoid arthritis

"Undruggable" targets



Transcriptions factors; fusion proteins; E3 ligases

STAT6 – T2 inflammatory diseases **DNAJB1-PRKACA** – liver cancer **CBL-B** – immuno-oncology





Nurix Is Advancing a Pipeline of Proprietary and Partnered Programs in Oncology and Inflammation & Immunology

Program	Target	MOA	Therapeutic area	Discovery – IND Lead Op enabling Phase 1a Phase 1b
NX-5948	ВТК	TPD	B-cell malignancies	
NX-2127	BTK-IKZF	TPD	B-cell malignancies	
NX-1607	CBL-B	TPE	Immuno-Oncology	
BRAF degrader	Pan-mutant BRAF	TPD	Solid tumors	
Multiple	Undisclosed	TPD/DAC	Undisclosed	
Multiple	Undisclosed	TPD	Undisclosed	GILEAD sanofi
Multiple	Undisclosed	DAC	Oncology	₽ Pfizer
NX-5948	BTK	TPD	Inflammation / autoimmune	
NX-0479/GS-6791	IRAK4	TPD	RA & inflammatory diseases	 ✓ GILEAD
STAT6 degrader	STAT6	TPD	T2 inflammatory diseases	sanofi
Multiple	Undisclosed	TPD	Inflammation / autoimmune	sanofi
Undisclosed	Undisclosed	TPD/DAC	Inflammation / autoimmune	



BRAF Mutations Activate the MAPK Pathway and Are Associated with Cancer





2021 US incidence⁴


5



Figure made in BioRender

¹ Owsley 2021 Exp Biol Med 2 NCI-SEER 2024, adjusted with Owsley %BRAF mutation rate in cancer type % 3 Mgmt of brain metastasis in melanoma - UpToDate 4 EvaluatePharma Epi for incidence by tumor type (2021, US), publication and GENIE/TCGA datasets for mutation prevalence by tumor types

Pan-Mutant BRAF Degrader: A Novel Approach for Broadly Targeting BRAF Mutations and Overcoming BRAFi Resistance



Targets mutant BRAF while sparing wildtype BRAF, which is critical for normal cellular function


Prevents dimer formation and avoids paradoxical activation

Degrader provides sustained MAPK pathway suppression through catalytic MoA


May delay and/or circumvent BRAFi-induced MAPK pathway resistance

NRX-0305 Is a Potent and Selective Pan-Mutant BRAF Degrader

Pan-Mutant BRAF Degradation




IMR-90 Global Proteomics, 50x DC50*




Log2 (Fold Change)

BRAF V600E Degradation by NRX-0305 Inhibits pERK, Induces Anti-Proliferative Activity and Circumvents Paradoxical Activation

pERK1/2 Inhibition




Viability




Concentration (µM)

Paradoxical Activation




Concentration (µM)

NRX-0305 Shows Improved Coverage of Clinically Relevant BRAF Mutations Compared to Other BRAF and RAF Agents




NRX-0305 Exhibits Dose-Proportional Pharmacokinetics and Pharmacodynamics Following a Single Oral Dose *In Vivo*




Brain Exposure Is a Key Component of Nurix *In Vivo* Screening, Allowing Identification of CNS Penetrant Degraders

Brain Exposure of BRAF Compounds



84% of *in vivo* screened compounds have measurable brain exposure

Mutant BRAF Tumor Degradation Correlates with Brain Exposure




Compounds that induce potent mutant BRAF degradation in subcutaneous tumors also exhibit high brain exposure



NRX-0305 Is CNS Penetrant with Favorable Cross-Species Bioavailability


Rat Plasma PK and Brain/Plasma Ratios




Bioavailability

NRX-0305	%F
Mouse	71
Rat	47
Cyno	28


NRX-0305 Demonstrates Efficacy in a Class 1 V600E Melanoma CDX Model




V600E Degradation




NRX-0305 Demonstrates Efficacy in a Class 1 V600E Melanoma Intracranial CDX Model




NRX-0305 Demonstrates Efficacy in a Class 2 K601E Melanoma CDX Model



Mutant BRAF Degradation




NRX-0305 Inhibits Tumor Growth in Numerous Class 1 Treatment-Resistant and Class 2/3 PDX Models




 NRX-0305 demonstrates antitumor activity in multiple PDX models in a 14-day exploratory screen

NRX-0305 Is Efficacious in a Class 3 D594N Bladder Cancer PDX Model and Synergizes with MEK Inhibition




NRX-0305 Synergizes with MEK Inhibition Leading to Complete Tumor Regression in a Class 3 D594N Bladder Cancer PDX Model

Individual Tumor Volumes



• NRX-0305 in combination with MEK inhibitor, Trametinib, results in complete tumor regressions


Catalytic MoA and Ability To Degrade Dimeric BRAF Mutants Provide an Opportunity To Clinically Benefit Patients who Have Progressed on BRAFi




• NRX-0305 is also predicted to have activity against BRAF splice variants and BRAF amplifications, thereby covering >50% of the BRAFi-resistant population




NRX-0305 Demonstrates Efficacy in a Class 1 (V600E, NRAS Q61R) Pembrolizumab+BRAFi-Resistant Melanoma PDX Model



V600E Degradation



Summary



NRX-0305 is an orally available and CNS penetrant pan-mutant BRAF degrader

Potent and selective towards Class 1/2/3 BRAF mutants while sparing wildtype BRAF

Prevents dimer formation and avoids paradoxical activation

Demonstrates broad anti-tumor efficacy in BRAF Class 1/2/3 and Class 1 treatment-resistant CDX and PDX models

Synergizes with MEKi to drive complete regressions in Class 3 BRAF mutant cancers

21

Acknowledgments

Thank you to the Nurix Research Team for making this work possible

